Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts.

Baganz L, Richter A, Albrecht K, Schneider M, Burmester GR, Zink A, Strangfeld A.

Semin Arthritis Rheum. 2018 Sep 17. pii: S0049-0172(18)30331-7. doi: 10.1016/j.semarthrit.2018.09.003. [Epub ahead of print]


Rheumatoid arthritis treatment in patients with a history of cancer.

Regierer AC, Strangfeld A.

Curr Opin Rheumatol. 2018 May;30(3):288-294. doi: 10.1097/BOR.0000000000000492.


[Revised version of the statement by the DGRh on biosimilars-update 2017].

Braun J, Lorenz HM, Müller-Ladner U, Schneider M, Schulze-Koops H, Specker C, Strangfeld A, Wagner U, Dörner T.

Z Rheumatol. 2018 Feb;77(1):81-90. doi: 10.1007/s00393-017-0407-0. German.


Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.

Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A.

Rheumatol Int. 2018 Apr;38(4):579-587. doi: 10.1007/s00296-017-3870-7. Epub 2017 Nov 16.


[Sepsis and mortality after severe infections : How epidemiological data confirm results of animal experiments].

Strangfeld A.

Z Rheumatol. 2017 Nov;76(9):776-779. doi: 10.1007/s00393-017-0374-5. German. No abstract available.


Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.

Mercer LK, Regierer AC, Mariette X, Dixon WG, Baecklund E, Hellgren K, Dreyer L, Hetland ML, Cordtz R, Hyrich K, Strangfeld A, Zink A, Canhao H, Hernandez MV, Tubach F, Gottenberg JE, Morel J, Zavada J, Iannone F, Askling J, Listing J.

Ann Rheum Dis. 2017 Dec;76(12):2025-2030. doi: 10.1136/annrheumdis-2017-211623. Epub 2017 Aug 19.


Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.

Meissner Y, Richter A, Manger B, Tony HP, Wilden E, Listing J, Zink A, Strangfeld A.

Ann Rheum Dis. 2017 Sep;76(9):1583-1590. doi: 10.1136/annrheumdis-2017-211209. Epub 2017 May 8.


[How frequent are poor prognostic markers in rheumatoid arthritis? : An estimate based on three epidemiologic cohorts].

Albrecht K, Richter A, Meissner Y, Huscher D, Baganz L, Thiele K, Schneider M, Strangfeld A, Zink A.

Z Rheumatol. 2017 Jun;76(5):434-442. doi: 10.1007/s00393-017-0306-4. German.


Primary and secondary patient data in contrast: the use of observational studies like RABBIT.

Richter A, Meißner Y, Strangfeld A, Zink A.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S79-S86. Epub 2016 Oct 19. Review.


[The first biologic for rheumatoid arthritis: factors influencing the therapeutic decision].

Pattloch D, Richter A, Manger B, Dockhorn R, Meier L, Tony HP, Zink A, Strangfeld A.

Z Rheumatol. 2017 Apr;76(3):210-218. doi: 10.1007/s00393-016-0174-3. German.


Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.

Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A.

Arthritis Res Ther. 2016 Aug 5;18(1):183. doi: 10.1186/s13075-016-1077-z.


Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.

Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, Aringer M, Meißner Y, Zink A, Listing J.

Ann Rheum Dis. 2017 Mar;76(3):504-510. doi: 10.1136/annrheumdis-2016-209773. Epub 2016 Jul 12.


Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases.

Albrecht K, Richter A, Callhoff J, Huscher D, Schett G, Strangfeld A, Zink A.

Arthritis Res Ther. 2016 Jun 23;18:149. doi: 10.1186/s13075-016-1043-9.


Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.

Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, Strangfeld A, Zink A, Mariette X, Finckh A, Canhao H, Iannone F, Zavada J, Morel J, Gottenberg JE, Hyrich KL, Listing J.

Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.


[Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].

Waldner MJ, Strangfeld A, Aringer M.

Z Rheumatol. 2016 Feb;75(1):13-21. doi: 10.1007/s00393-015-0033-7. Review. German.


[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].

Schmalzing M, Strangfeld A, Tony HP.

Z Rheumatol. 2016 Feb;75(1):22-31. doi: 10.1007/s00393-015-0034-6. Review. German.


Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.

Richter A, Listing J, Schneider M, Klopsch T, Kapelle A, Kaufmann J, Zink A, Strangfeld A.

Ann Rheum Dis. 2016 Sep;75(9):1667-73. doi: 10.1136/annrheumdis-2015-207838. Epub 2015 Nov 13.


Epidemiologie und gegenwärtige Versorgung von Patienten mit muskuloskelettalen Erkrankungen--Überblick.

Strangfeld A.

Drug Res (Stuttg). 2015 Nov;65 Suppl 1:S3-4. doi: 10.1055/s-0035-1558081. Epub 2015 Nov 4. German. No abstract available.


Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT.

Gerhold K, Richter A, Schneider M, Bergerhausen HJ, Demary W, Liebhaber A, Listing J, Zink A, Strangfeld A.

Rheumatology (Oxford). 2015 Oct;54(10):1858-66. doi: 10.1093/rheumatology/kev194. Epub 2015 May 21.


[How do register data support clinical decision-making?].

Strangfeld A, Richter A.

Z Rheumatol. 2015 Mar;74(2):119-24. doi: 10.1007/s00393-014-1449-1. German.


[Safety of biologic therapy - results from the German biologics register RABBIT].

Strangfeld A, Zink A.

Dtsch Med Wochenschr. 2014 Sep;139(37):1817-20. doi: 10.1055/s-0034-1370252. Epub 2014 Sep 2. Review. German. No abstract available.


[Prophylaxis and treatment of infections in elderly patients with rheumatism].

Kneitz C, Strangfeld A, Krüger K.

Z Rheumatol. 2014 Apr;73(3):225-32. doi: 10.1007/s00393-013-1243-5. German.


[Safety of antirheumatic drug treatment in the elderly].

Krüger K, Strangfeld A, Kneitz C.

Z Rheumatol. 2014 Apr;73(3):244-50. doi: 10.1007/s00393-013-1245-3. Review. German.


Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics register.

Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, Zink A.

Arthritis Care Res (Hoboken). 2014 Nov;66(11):1627-33. doi: 10.1002/acr.22327.


Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A.

Ann Rheum Dis. 2015 Feb;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021. Epub 2013 Nov 29.


Evaluation of the RABBIT Risk Score for serious infections.

Zink A, Manger B, Kaufmann J, Eisterhues C, Krause A, Listing J, Strangfeld A.

Ann Rheum Dis. 2014 Sep;73(9):1673-6. doi: 10.1136/annrheumdis-2013-203341. Epub 2013 Jun 5.


Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report.

Aringer M, Burkhardt H, Burmester GR, Fischer-Betz R, Fleck M, Graninger W, Hiepe F, Jacobi AM, Kötter I, Lakomek HJ, Lorenz HM, Manger B, Schett G, Schmidt RE, Schneider M, Schulze-Koops H, Smolen JS, Specker C, Stoll T, Strangfeld A, Tony HP, Villiger PM, Voll R, Witte T, Dörner T.

Lupus. 2012 Apr;21(4):386-401. doi: 10.1177/0961203311426569. Epub 2011 Nov 9. Review.


Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, Listing J.

Ann Rheum Dis. 2011 Nov;70(11):1914-20. doi: 10.1136/ard.2011.151043. Epub 2011 Jul 25.


[The importance of patient perspective in drug surveillance systems].

Gäwert L, Hierse F, Zink A, Strangfeld A.

Z Rheumatol. 2010 Nov;69(9):795-802. doi: 10.1007/s00393-010-0642-0. German.


Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers.

Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, Neovius M, Simard J, Symmons D, Watson K, Zink A.

Rheumatology (Oxford). 2011 Jan;50(1):146-51. doi: 10.1093/rheumatology/keq301. Epub 2010 Sep 22.


Therapy: Assessing cancer risk of cytokine inhibitors in RA.

Strangfeld A, Zink A.

Nat Rev Rheumatol. 2010 Mar;6(3):126-7. doi: 10.1038/nrrheum.2010.21. No abstract available.


Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A.

Arthritis Res Ther. 2010;12(1):R5. doi: 10.1186/ar2904. Epub 2010 Jan 8.


Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.

Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.

JAMA. 2009 Feb 18;301(7):737-44. doi: 10.1001/jama.2009.146.


Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.

Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.

Ann Rheum Dis. 2009 Dec;68(12):1856-62. doi: 10.1136/ard.2008.098467. Epub 2009 Jan 6.


Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.


Infection and musculoskeletal conditions: Bacterial and opportunistic infections during anti-TNF therapy.

Strangfeld A, Listing J.

Best Pract Res Clin Rheumatol. 2006 Dec;20(6):1181-95. Review.


Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J.

Arthritis Rheum. 2006 Nov;54(11):3399-407.


Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.

Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A.

Arthritis Res Ther. 2006;8(3):R66. Epub 2006 Apr 5.


[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT].

Zink A, Listing J, Strangfeld A, Gromnica-Ihle E, Demary W, Schneider M.

Z Rheumatol. 2006 Sep;65(5):441-6. German.


Infections in patients with rheumatoid arthritis treated with biologic agents.

Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A.

Arthritis Rheum. 2005 Nov;52(11):3403-12.


Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980-88.

Kiessling U, Döring E, Listing J, Meincke J, Schöntube M, Strangfeld A, Zink A.

J Rheumatol. 1998 Sep;25(9):1837-43.


Supplemental Content

Loading ...
Support Center